CL2014003148A1 - Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición. - Google Patents

Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.

Info

Publication number
CL2014003148A1
CL2014003148A1 CL2014003148A CL2014003148A CL2014003148A1 CL 2014003148 A1 CL2014003148 A1 CL 2014003148A1 CL 2014003148 A CL2014003148 A CL 2014003148A CL 2014003148 A CL2014003148 A CL 2014003148A CL 2014003148 A1 CL2014003148 A1 CL 2014003148A1
Authority
CL
Chile
Prior art keywords
guanidine
injection
therapeutic agent
aqueous pharmaceutical
pharmaceutical composition
Prior art date
Application number
CL2014003148A
Other languages
English (en)
Inventor
David Schmitt
Hans-Joachim Wallny
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48534372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003148(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2014003148A1 publication Critical patent/CL2014003148A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
CL2014003148A 2012-05-25 2014-11-20 Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición. CL2014003148A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261651588P 2012-05-25 2012-05-25

Publications (1)

Publication Number Publication Date
CL2014003148A1 true CL2014003148A1 (es) 2015-02-27

Family

ID=48534372

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003148A CL2014003148A1 (es) 2012-05-25 2014-11-20 Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.

Country Status (16)

Country Link
US (1) US10010513B2 (es)
EP (1) EP2854760B1 (es)
JP (3) JP6250646B2 (es)
KR (1) KR20150024301A (es)
CN (1) CN104220047B (es)
AR (1) AR091155A1 (es)
AU (2) AU2013265255B2 (es)
CA (1) CA2866232A1 (es)
CL (1) CL2014003148A1 (es)
CO (1) CO7270463A2 (es)
ES (1) ES2706059T3 (es)
MX (1) MX2014014318A (es)
PH (1) PH12014502352A1 (es)
RU (1) RU2014152803A (es)
WO (1) WO2013174936A1 (es)
ZA (1) ZA201406403B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3808338A1 (en) 2013-09-11 2021-04-21 Eagle Biologics, Inc. Liquid protein formulations containing ionic liquids
US10414816B2 (en) * 2014-03-11 2019-09-17 Green Cross Holdings Corporation Method for purifying immunoglobulin
WO2016054259A1 (en) * 2014-10-01 2016-04-07 Arsia Therapeutics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US11406591B2 (en) * 2015-02-09 2022-08-09 University Of Louisville Research Foundation, Inc. Ophthalmic compositions and methods for reducing oxidative damage to an eye lens
WO2017094507A1 (ja) * 2015-11-30 2017-06-08 ロート製薬株式会社 眼科組成物
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
TWI656882B (zh) * 2016-08-10 2019-04-21 南韓商賽特瑞恩股份有限公司 穩定的液體抗流感病毒抗體醫藥調配物
KR102262743B1 (ko) * 2017-07-07 2021-06-09 에이치케이이노엔 주식회사 주사용 조성물
GB201713660D0 (en) * 2017-08-25 2017-10-11 Kalvista Pharmaceuticals Ltd Pharmaceutical compositions
CA3083113A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364884A (en) * 1993-01-21 1994-11-15 Baylor College Of Medicine Arginine compounds as ocular hypotensive agents
US5658948A (en) * 1994-03-02 1997-08-19 Allergan Enhancement of benzalkonium chloride preservative activity in formulations containing an incompatible drug using amino acids having net positive charge
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6462071B1 (en) * 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
DK1313415T3 (da) 2000-08-30 2008-10-13 Univ Johns Hopkins Indretninger til intraokulær lægemiddeladministration
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
MX2009010181A (es) * 2007-03-22 2009-12-04 Novartis Ag Antigenos c5 y usos de los mismos.
DK2328616T3 (en) 2008-08-05 2015-07-20 Novartis Ag Compositions and Methods for Antibodies to Complement Protein C5
WO2011084750A1 (en) * 2009-12-21 2011-07-14 Genentech, Inc. Antibody formulation
JP2013520476A (ja) * 2010-02-26 2013-06-06 ノヴォ ノルディスク アー／エス 安定な抗体含有組成物

Also Published As

Publication number Publication date
EP2854760B1 (en) 2018-10-17
WO2013174936A1 (en) 2013-11-28
AR091155A1 (es) 2015-01-14
EP2854760A1 (en) 2015-04-08
ES2706059T3 (es) 2019-03-27
AU2013265255A1 (en) 2014-09-25
MX2014014318A (es) 2015-02-12
RU2014152803A (ru) 2016-07-20
CN104220047B (zh) 2019-11-15
ZA201406403B (en) 2019-01-30
JP6405406B2 (ja) 2018-10-17
US10010513B2 (en) 2018-07-03
JP2018193406A (ja) 2018-12-06
CA2866232A1 (en) 2013-11-28
JP2017122123A (ja) 2017-07-13
PH12014502352A1 (en) 2015-01-12
AU2018203929A1 (en) 2018-06-21
JP6250646B2 (ja) 2017-12-20
US20130317457A1 (en) 2013-11-28
CN104220047A (zh) 2014-12-17
CO7270463A2 (es) 2015-05-19
JP2015517556A (ja) 2015-06-22
AU2013265255B2 (en) 2018-03-29
KR20150024301A (ko) 2015-03-06

Similar Documents

Publication Publication Date Title
CL2014003148A1 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.
CL2014002258A1 (es) Anticuerpos dirigidos contra metaloproteinasas de matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que lo contiene; y sus usos.
CL2014003256A1 (es) Composición que comprende un agente de control biológico y un fungicida.
CL2014003258A1 (es) Composición que comprende un agente de control biológico y un fungicida.
ES2964813T3 (es) Conjugados de fármacos que comprenden anticuerpos contra claudina 18.2
CL2014003269A1 (es) Composiciones que comprenden un agente de control biológico y un fungicida.
CL2014003272A1 (es) Composición que comprende un agente de control biológico y un fungicida.
CL2014003271A1 (es) Composición que comprende un agente de control biológico y un fungicida.
CL2014001930A1 (es) Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2).
CL2015001431A1 (es) Composición que comprende un agente de control biológico y un insecticida
BR112014029906A2 (pt) composições compreendendo um agente de controle biológico e um inseticida.
CL2015001432A1 (es) Composición que comprende un agente de control biológico y un fungicida
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
CL2014002282A1 (es) Anticuerpos contra la metaloproteinasa de la matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que la contiene; y sus usos.
BR112014029122A2 (pt) composições que compreendem um agente de controle biológico e um inseticida
BR112014029222A2 (pt) composições que compreendem um agente de controle biológico e um inseticida
BRPI0815577A2 (pt) Peptídeo foxm1 e agente medicinal compreendendo o mesmo.
BR112014029118A2 (pt) composições que compreendem um agente de controle biológico e um inseticida
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
EP3068442A4 (en) Bionanofluid for use as a contrast, imaging, disinfecting and/or therapeutic agent
BRPI1014390A2 (pt) composto de sal de amônio quaternário, composição medicinal, e, agente preventivo ou terapêutico
ZA201508454B (en) Method of applying a composition and pharmaceutical composition with a regimen of administering it, including photo-activating the active component
CL2014003332A1 (es) Una composicion que comprende un plaguicida solido insoluble en agua, un plaguicida soluble en agua, un agente reologico y un agente humectante-dispersante.
CL2014002414A1 (es) Composicion farmaceutica inyectable que comprende ibuprofeno, una solucion acuosa y un agente solubilizante seleccionado de fosfatos de sodio, de potasio, carbonatos de sodio, de potasio y/o combinaciones de ellos.
IL240949B (en) Aqueous pharmaceutical formulation for use in the treatment of type 1 or type 2 juvenile diabetes